NasdaqGS:ZYMEBiotechs
Zymeworks (ZYME) Is Up 5.4% After New FDA Approval Triggers $250 Million Milestone Payment
The U.S. FDA has approved Ziihera (zanidatamab-hrii), a bispecific HER2-targeting antibody, as a first-line treatment for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, triggering a US$250 million regulatory milestone payment from Jazz Pharmaceuticals to Zymeworks.
This second FDA approval for zanidatamab in under two years further validates Zymeworks’ Azymetric bispecific antibody platform and strengthens its royalty- and...